Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of cabozantinib-s-malate in patients with refractory thyroid cancer has been completed, with results posted in 2018. The study evaluated multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Oncocytic Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma
• Thyroid Carcinoma

Drugs mentioned

• COMETRIQ (CABOZANTINIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-03